Sign in

    Mazi Alimohamed

    Senior Equity Research Analyst at Leerink Partners

    Mazi Alimohamed, M.D., MPH is a Senior Equity Research Analyst at Leerink Partners, focusing on Diversified Biopharmaceuticals with coverage of key companies such as Amarin Corporation, Xencor, Zai Lab, 4D Molecular Therapeutics, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Zymeworks. He is recognized for his advanced quantitative approach to healthcare and specialty therapeutics research, consistently providing earnings projections and ratings, and maintaining sector outperformance ratings in his coverage universe. Alimohamed joined Leerink Partners in the early 2020s after earning medical and public health credentials, and has rapidly developed a reputation for integrity and rigor in equity research. He is FINRA-registered (CRD# 7971901) and holds the necessary securities licenses for equity research analysts.

    Mazi Alimohamed's questions to AMARIN CORP PLC\UK (AMRN) leadership

    Mazi Alimohamed's questions to AMARIN CORP PLC\UK (AMRN) leadership • Q1 2025

    Question

    Mazi Alimohamed of Leerink Partners asked about Amarin's plans for generating additional real-world evidence or clinical data to expand VASCEPA's labeling or strengthen its differentiation against generics and emerging lipid management therapies.

    Answer

    President and CEO Aaron Berg and executive Steven Ketchum responded. Berg stated that Amarin is continuously generating new data to differentiate the product, highlighting its unique ability to address residual cardiovascular risk. Ketchum added that the company continues to mine the rich REDUCE-IT dataset, present findings at major medical congresses on mechanisms of action, and support external collaborations to reinforce the drug's scientific foundation.

    Ask Fintool Equity Research AI